Additive effects of trastuzumab and genistein on human breast cancer cells

Anti-Cancer Drugs

Volumn 22, Issue 3, 2011, Pages 253-261

  Lattrich, Claus ^a   Lubig, Julia ^a   Springwald, Anette ^a   Goerse, Regina ^a   Ortmann, Olaf ^a   Treeck, Oliver ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

breast cancer; estrogen receptor b; genistein; HER2; trastuzumab

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; AURORA A KINASE; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN A2; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; DIARYLPROPIONITRILE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA1; ESTROGEN RECEPTOR BETA2; GENISTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; KI 67 ANTIGEN; MESSENGER RNA; ONCOPROTEIN; PROTEIN C FOS; PROTEIN MYBL2; SURVIVIN; TAMOXIFEN; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENISTEIN; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 79951680456     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283427bb5     Document Type: Article

References (48)

1. Treeck O, Lattrich C, Springwald A, Ortmann O. Estrogen receptor-β exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 2010; 120: 557-565.
2. Bardin A, Boulle N, Lazennec G,Vignon F, Pujol P. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004; 11:537-551. (Pubitemid 39331282)
3. Beeghly-Fadiel A, Kataoka N, Shu XO, Cai Q, Deming SL, Gao YT, et al. Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study. Oncol Rep 2008; 19:1347-1354.
4. Browne BC, O'Brien N, Duffy MJ, Crown J, O'Donovan N. HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets 2009; 9:419-438.
5. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21:309-318. (Pubitemid 29157789)
6. Messina M, Wu AH. Perspectives on the soy breast cancer relation. Am J Clin Nutr 2009; 89:1673S-1679S.
7. Taylor CK, Levy RM, Elliott JC, Burnett BP. The effect of genistein aglycone on cancer and cancer risk: a review of in-vitro, preclinical, and clinical studies. Nutr Rev 2009; 67:398-415.
8. Martin PM, Horwitz KB, Ryan DS, McGuire WL. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 1978; 103:1860-1867. (Pubitemid 9052644)
9. King RA, Bursill DB. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 1998; 67:867-872. (Pubitemid 28196660)
10. Adlercreutz H, Hamalainen E, Gorbach S, Goldin B. Dietary phyto-oestrogens and the menopause in Japan. Lancet 1992; 339:1233.
11. Nikov GN, Hopkins NE, Boue S, Alworth WL. Interactions of dietary estrogens with human estrogen receptors and the effect on estrogen receptor-estrogen response element complex formation. Environ Health Perspect 2000; 108:867-872.
12. Umekita Y, Souda M, Ohi Y, Sagara Y, Rai Y, Takahama T, et al. Expression of wild-type estrogen receptor-β protein in human breast cancer: specific correlation with HER2/neu overexpression. Pathol Int 2006; 56:423-427. (Pubitemid 44035906)
13. Stahlberg A, Aman P, Ridell B, Mostad P, Kubista M. Quantitative real-time PCR method for detection of B-lymphocyte monoclonality by comparison of? and a; immunoglobulin light chain expression. Clin Chem 2003; 49:51-59. (Pubitemid 36078553)
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-?-? C(T)) method. Methods 2001; 25:402-408. (Pubitemid 34164012)
15. Tokuda Y, Suzuki Y, Saito Y, Umemura S. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review. Breast Cancer 2009; 16:295-300.
16. Li Y, Upadhyay S, Bhuiyan M, Sarkar FH. Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 1999; 18:3166-3172. (Pubitemid 29261238)
17. Banerjee S, Li Y, Wang Z, Sarkar FH. Multitargeted therapy of cancer by genistein. Cancer Lett 2008; 269:226-242.
18. Xiao Y, Gao X, Maragh S, Telford WG, Tona A. Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer. Clin Chem 2009; 55:1307-1315.
19. Sakla MS, Shenouda NS, Ansell PJ, Macdonald RS, Lubahn DB. Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells. Endocrine 2007; 32:69-78. (Pubitemid 350242549)
20. Shadeo A, Lam WL. Comprehensive copy number profiles of breast cancer cell model genomes. Breast Cancer Res 2006; 8:R9.
21. Prat A, Baselga J. The role of hormonal therapy in the management of hormonal receptor-positive breast cancer with coexpression of HER2. Nat Clin Pract Oncol 2008; 5:531-542.
22. Olszewski WT, Mrozkowiak A, Olszewski WP, Krzakowski MJ. Coexpression of steroid and HER2 receptors in breast carcinomas in a large (4493 cases) population-based Polish study. J Clin Oncol (Meeting Abstracts) 2005; 23:797.
23. Reiner GCA, Katzenellenbogen BS, Bindal RD, Katzenellenbogen JA. Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells. Cancer Res 1984; 44:2302-2308. (Pubitemid 14110640)
24. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand-binding specificity and transcript tissue distribution of estrogen receptors-α and β. Endocrinology 1997; 138:863-870. (Pubitemid 27089735)
25. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93:5925-5930. (Pubitemid 26190778)
26. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH,Van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor-β. Endocrinology 1998; 139:4252-4263. (Pubitemid 28513713)
27. Treeck O, Juhasz-Boess I, Lattrich C, Horn F, Goerse R, Ortmann O. Effects of exon-deleted estrogen receptor-β transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Res Treat 2008; 110:507-520. (Pubitemid 351962596)
28. George PS, Kailas M, Sandra MB, Pauline JC, Sally L, Kieran H, et al. Reduced expression of oestrogen receptor-β in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. J Pathol 2003; 201:213-220.
29. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC Estrogen receptor-β inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004; 64:423-428. (Pubitemid 38114127)
30. Iwasaki M, Inoue M, Otani T, Sasazuki S, Kurahashi N, Miura T, et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol 2008; 26:1677-1683.
31. Chang EC, Charn TH, Park SH, Helferich WG, Komm B, Katzenellenbogen JA, et al. Estrogen receptors α and β as determinants of gene expression: influence of ligand, dose, and chromatin binding. Mol Endocrinol 2008; 22:1032-1043. (Pubitemid 351629605)
32. Ogawara H, Akiyama T, Ishida J, Watanabe S, Suzuki K. A specific inhibitor for tyrosine protein kinase from Pseudomonas. J Antibiot (Tokyo) 1986; 39:606-608. (Pubitemid 16114499)
33. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262:5592-5595.
34. Akiyama T, Ogawara H. Use and specificity of genistein as inhibitor of protein tyrosine kinases. Methods Enzymol 1991; 201:362-370.
35. Hunter T, Cooper JA. Protein tyrosine kinases. Annu Rev Biochem 1985; 54:897-930.
36. Sotoca AM, Ratman D, Van der Saag P, Strom A, Gustafsson JA, Vervoort J, et al. Phytoestrogen-mediated inhibition of proliferation of the human T47D breast cancer cells depends on the ERα/ERβ ratio. J Steroid Biochem Mol Biol 2008; 112:171-178.
37. Kauraniemi P, Hautaniemi S, Autio R, Astola J, Monni O, Elkahloun A, et al. Effects of herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 2003; 23:1010-1013.
38. Schultze-Mosgau MH, Dale IL, Gant TW, Chipman JK, Kerr DJ, Gescher A. Regulation of c-fos transcription by chemopreventive isoflavonoids and lignans in MDA-MB-468 breast cancer cells. Eur J Cancer 1998; 34:1425-1431. (Pubitemid 28370936)
39. Li Y, Bhuiyan M, Sarkar FH. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int J Oncol 1999; 15:525-533.
40. Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009; 69:1416-1428.
41. Chrzan BG, Bradford PG. Phytoestrogens activate estrogen receptor-β1 and estrogenic responses in human breast and bone cancer cell lines. Mol Nutr Food Res 2007; 51:171-177. (Pubitemid 47086240)
42. Xu S-Z, Zhong W, Ghavideldarestani M, Saurabh R, Lindow SW, Atkin SL. Multiple mechanisms of soy isoflavones against oxidative stress-induced endothelium injury. Free Radic Biol Med 2009; 47:167-175.
43. 2 in genistein-induced expression of p21 waf1/cip1 in PC-3 prostate cancer cells. Anticancer Research 2008; 28:709-714. (Pubitemid 351578912)
44. Park HJ, Della-Fera MA, Hausman DB, Rayalam S, Ambati S, Baile CA. Genistein inhibits differentiation of primary human adipocytes. The Journal of Nutritional Biochemistry 2009; 20:140-148.
45. Maruyama K, Endoh H, Sasaki-Iwaoka H, Kanou H, Shimaya E, Hashimoto S, et al. A novel isoform of rat estrogen receptor-β with 18 amino acid insertion in the ligand binding domain as a putative dominant negative regular of estrogen action. Biochem Biophys Res Commun 1998; 246:142-147. (Pubitemid 28413942)
46. Morton M S, Arisaka O, Miyake N, Morgan LD, Evans BAJ. Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 2002; 132:3168-3171.
47. Busby MG, Jeffcoat AR, Bloedon LT, Koch MA, Black T, Dix KJ, et al. Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men. Am J Clin Nutr 2002; 75:126-136. (Pubitemid 34013498)
48. Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, et al. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 2003; 77:875-882.